What It Is
Cagrilintide is a long-acting synthetic analog of amylin, a hormone the pancreas releases alongside insulin to help regulate satiety and post-meal metabolism. Researchers modified native amylin's structure to resist the fibril formation that limits its natural stability, extending its duration of action enough for once-weekly dosing. Cagrilintide has been studied on its own, but it is best known as the amylin component of CagriSema, an investigational once-weekly combination with the GLP-1 receptor agonist semaglutide, both under development by Novo Nordisk for chronic weight management.
How It Works
Cagrilintide acts on a family of calcitonin-related receptors, including amylin receptor subtypes and the calcitonin receptor itself; pharmacology databases classify it as a nonselective agonist across this receptor family, and a 2025 structural study mapped how the molecule binds these receptor complexes.[5] Through this activity, cagrilintide is thought to slow gastric emptying, promote satiety, and reduce food intake — effects similar to those documented for the older, FDA-approved amylin analog pramlintide. Because semaglutide works through a separate GLP-1 receptor pathway, combining the two is intended to produce complementary appetite and weight effects, though receptor activity alone does not guarantee a clinical outcome.
What the Research Shows
Cagrilintide has advanced through a genuine human clinical development program rather than staying at the mechanism stage. A phase 2 trial in adults with overweight or obesity found greater weight loss with once-weekly cagrilintide alone than with placebo.[6] In combination with semaglutide, two pivotal phase 3 trials — REDEFINE 1 (overweight or obesity) and REDEFINE 2 (overweight or obesity with type 2 diabetes) — reported substantially greater weight reduction with CagriSema than placebo over 68 weeks.[9][10] Novo Nordisk's regulatory filing announcement cited roughly 20-23% average body-weight reduction with CagriSema versus 2-3% with placebo, along with improved blood-sugar control in the diabetes trial.[11] A later head-to-head trial against tirzepatide reported about 23% weight loss with CagriSema but did not meet its pre-specified non-inferiority target.[20] These are real trial results, though they largely describe the cagrilintide-semaglutide combination rather than cagrilintide alone, and data beyond 68 weeks are not yet available.
Safety & Side Effects
The dominant safety signal across CagriSema trials has been gastrointestinal: nausea, constipation, and vomiting occurred in roughly 73-80% of CagriSema-treated participants across the two REDEFINE trials, versus about 34-40% on placebo, mostly described as transient and mild to moderate.[9][10] Because CagriSema combines cagrilintide with semaglutide, much of its established warning profile comes from semaglutide's own labeling rather than cagrilintide-specific data, including:
- Acute pancreatitis and gallbladder disease
- Hypoglycemia risk when used with insulin or other glucose-lowering medicines
- Kidney injury related to dehydration from vomiting or diarrhea
- Increased heart rate and, in people with type 2 diabetes, diabetic retinopathy complications
Cagrilintide-specific long-term safety, pregnancy, and drug-interaction data remain limited in the absence of a standalone approved label.[14]
Regulatory Status
As of Novo Nordisk's December 2025 regulatory filing announcement, CagriSema (cagrilintide 2.4 mg plus semaglutide 2.4 mg) had been submitted to the FDA for weight-management approval but was not yet approved in the United States or European Union.[11] A subsequent company update stated that an FDA decision was anticipated by late 2026, though company timelines are not the same as approval.[20] Cagrilintide as a standalone drug has no approved label anywhere. Regulatory status here can change quickly, so current approval status should always be verified against FDA or EMA records rather than assumed. FDA has separately warned about unapproved GLP-1-related products sold online with unreliable labeling or inconsistent active-ingredient content, a caution relevant to any cagrilintide product marketed outside a supervised clinical trial.[13]